A Brazilian startup supported by the São Paulo Research Foundation (FAPESP) has developed biomaterials that significantly reduce the risk of medical implant failure by improving how implants interact with human cells. The company, Extremus Smart Surfaces, is pioneering a microscopic surface treatment that transforms conventional implants into biologically active devices, accelerating healing and reducing complications. This innovation addresses a persistent problem in medicine, where implants such as dental, orthopedic, and cardiovascular devices often fail due to poor integration with surrounding tissue.
Traditional implants are designed to provide mechanical support, but they do not actively engage with the biological environment. As a result, patients frequently experience rejection, infection, or loosening of the implant. Studies show that orthopedic patients face complication rates as high as thirty-two percent within the first month after surgery, while dental implants have failure rates of around seven percent. These numbers highlight the urgent need for solutions that go beyond mechanical fixation.
The Extremus technology uses nanotopography, a microscopic structural pattern etched into the implant surface, to guide stem cells toward bone-forming differentiation. By encouraging stem cells to become osteoblasts, the treated surface improves fixation and accelerates recovery. This approach reduces the likelihood of rejection and enhances the long-term stability of implants. The company describes its innovation as a paradigm shift, moving implants from passive devices to active participants in the healing process.
The potential applications are broad. Dental implants represent a major market, with Brazil alone performing more than eight hundred thousand procedures annually. Globally, the dental implant market was valued at 4.6 billion dollars in 2023 and is projected to grow by more than six percent per year. Orthopedic implants, including hip and knee replacements, also stand to benefit from improved integration. Cardiovascular devices may see the greatest impact, since circulatory failure carries high risks and demands reliable long-term performance.
Extremus does not manufacture implants directly. Instead, it licenses its technology to implant producers, enabling them to incorporate the surface treatment into existing products. This business model allows rapid scaling and adoption across multiple medical fields. The company is pursuing regulatory approval through ANVISA, Brazil’s health authority, and is preparing to expand internationally once approvals are secured.
The innovation also represents a fabrication breakthrough. Creating precise nanotopography requires advanced engineering techniques, but the company has developed a scalable process that can be applied to a wide range of implant materials. By combining engineering with biology, Extremus is contributing to a new generation of medical devices that are safer, more effective, and more patient-centered.
Article from FAPESP: Biomaterials reduce the chance of medical implant failure
